Graco Inc (NYSE:GGG). reported its fourth-quarter 2024 earnings, revealing a diluted earnings per share (EPS) of $0.64, missing the forecasted $0.77. The company's revenue reached $548.1 million, ...

Graco's Q4 EPS fell short of expectations, impacting stock performance. Revenue decreased by 3% year-over-year, aligning with industry challenges. The company completed a major reorganization ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD ...